Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Management of Neurological Disorders:Dementia
JNNP 57:1451-1456, Rossor,M.N., 1994
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005
High-Dose Estradiol Improves Cognition for Women with AD, Results of a Randomized Study
Neurol 57:605-612, Asthana,S.,et al, 2001
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Nonsteroidal Anti-Inflammatory Drug use and Alzheimer-Type Pathology in Aging
Neurol 50:986-990, Mackenzie,I.&Munoz,D.G., 1998
Long-Term Tacrine (Cognex) Treatment:Effects on Nursing Home Placement and Mortality
Neurol 47:166-177, Knopman,D.,et al, 1996
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993